“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Tom Parmakellis Biography and Net Worth

Director of GBS

Dr. Tom Parmakellis has 25 years’ experience as a medical practitioner. Having negotiated exclusive distribution rights for internationally recognized medical lasers in Australia, Dr Parmakellis’s experience in healthcare markets reaches back to 1996 when he introduced Laser Hair removal into the Australian market.

In 2009, Dr Parmakellis founded Lookfresh Cosmestic Medicine, which he still owns today, and in 2017 he founded SkinLift Ultherapy.

Dr. Parmakellis holds a MBBS from the University of Sydney, is a fellow of the Royal Australian College of General Practitioners (FRACGP) and a fellow of the Cosmetic Physicians College Australasia (FCPCA).

What is Tom Parmakellis' net worth?: The estimated net worth of Tom Parmakellis is at least $1,480.00 as of June 21st, 2021. Dr. Parmakellis owns 1,000 shares of GBS stock worth more than $1,480 as of November 17th. This net worth evaluation does not reflect any other assets that Dr. Parmakellis may own. Learn More about Tom Parmakellis' net worth.
How do I contact Tom Parmakellis?: The corporate mailing address for Dr. Parmakellis and other GBS executives is , , . GBS can also be reached via phone at 646 828 8258 and via email at [email protected]. Learn More on Tom Parmakellis' contact information.
Has Tom Parmakellis been buying or selling shares of GBS?: Tom Parmakellis has not been actively trading shares of GBS within the last three months. Most recently, on Thursday, December 16th, Tom Parmakellis bought 2,800 shares of GBS stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $4,732.00. Learn More on Tom Parmakellis' trading history.
Who are GBS's active insiders?: GBS's insider roster includes Tom Parmakellis (Director), and Spiro Sakiris (Insider). Learn More on GBS's active insiders.

Tom Parmakellis Insider Trading History at GBS

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2021	Buy	2,800	$1.69	$4,732.00
9/28/2021	Buy	1,000	$2.40	$2,400.00
6/21/2021	Buy	1,000	$4.44	$4,440.00	1,000

Tom Parmakellis Buying and Selling Activity at GBS

GBS Company Overview

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Today's Range

Now: $1.48

$1.45

$1.52

50 Day Range

MA: $1.61

$0.47

$2.24

2 Week Range

Now: $1.48

$0.36

$2.89

Volume

95,812 shs

Average Volume

955,325 shs

Market Capitalization

$22.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate